Evidence map›Paper›PMID 32692379›Full record

ArticleJAMA2020

Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019.

Jenny S Guadamuz, Dima M Qato, G Caleb Alexander

Abstract read
In one paragraph

Article in JAMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jenny S GuadamuzDepartment of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago College of Pharmacy.
Dima M QatoDepartment of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago College of Pharmacy.
G Caleb AlexanderCenter for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CertificationDrug IndustryDrug LabelingDrug-Related Side Effects and Adverse ReactionsProgram DevelopmentProgram EvaluationRegistriesRisk Evaluation and MitigationTime FactorsUnited StatesUnited States Food and Drug Administration

Identifiers

PMID32692379
PMCPMC12543398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.